Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases.
Collegium has developed a novel, patented, abuse-deterrent technology platform, DETERx®, designed to provide extended-release drug delivery, while safeguarding against common methods of abuse and tampering including crushing, chewing, heating and injecting.
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. While abuse of Xtampza ER is still possible, FDA has determined that the product has abuse-deterrent properties. The Xtampza ER label supports alternate administration options, including, sprinkling the capsule contents on soft foods or into a cup, and then directly into the mouth, or through a gastrostomy or nasogastric feeding tube.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|
9:00 a.m. ET
2:40 p.m. CT